(Q43608246)

25 November 2017

Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma (English)

1 reference

25 November 2017

Niklaus G Schaefer

1

1 reference

25 November 2017

Jean F Geschwind

2

1 reference

25 November 2017

James Engles

3

1 reference

25 November 2017

Julia W Buchanan

4

1 reference

25 November 2017

Richard L Wahl

5

1 reference

25 November 2017

22 September 2011

1 reference

25 November 2017

Translational Research

1 reference

25 November 2017

159

1 reference

25 November 2017

1

1 reference

25 November 2017

51-57

1 reference

On the Origin of Cancer Cells

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Glycolysis inhibition for anticancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Novel intraarterial therapy for liver cancer using ethylbromopyruvate dissolved in an iodized oil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Spectrophotometric determination of bromopyruvate by reaction with 2-nitro-5-thiobenzoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.08.008

10.1016/J.TRSL.2011.08.008

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference